Issue 16, 2017

Semi-continuous multi-step synthesis of lamivudine

Abstract

We report the first continuous flow synthesis of lamivudine, an antiretroviral drug used in the treatment of HIV/AIDS and hepatitis B. The key intermediate (5-acetoxy oxathiolane) was prepared by an integrated two step continuous flow process from L-menthyl glyoxalate hydrate in a single solvent, in 95% overall conversion. For the crucial glycosidation reaction, using pyridinium triflate as the novel catalyst, an improved conversion of 95% was obtained. The overall isolated yield of the desired isomer of lamivudine (40%) was improved in the flow synthesis compared to the batch process.

Graphical abstract: Semi-continuous multi-step synthesis of lamivudine

Supplementary files

Article information

Article type
Paper
Submitted
25 Feb 2017
Accepted
27 Mar 2017
First published
27 Mar 2017

Org. Biomol. Chem., 2017,15, 3444-3454

Semi-continuous multi-step synthesis of lamivudine

D. Mandala, S. Chada and P. Watts, Org. Biomol. Chem., 2017, 15, 3444 DOI: 10.1039/C7OB00480J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements